Ligand id: 4860

Name: adalimumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: adalimumab

Compound class Antibody
Approved drug? Yes (FDA (2002), EMA (2003))
International Nonproprietary Names
INN number INN
7860 adalimumab
D2E7 [5] | FKB327 | Humira®
Database Links
Specialist databases
IMGT/mAb-DB 165
Other databases
PubChem SID 178101561
Search PubMed clinical trials adalimumab
Search PubMed titles adalimumab
Search PubMed titles/abstracts adalimumab
Wikipedia Adalimumab
Adalimumab is an anti-TNFα monoclonal antibody with immunosuppresive activity [5]. It was the first fully human monoclonal antibody drug approved by the FDA.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilar drugs: In September 2016, the US FDA approved Amjevita® (ZRC-3197 [1], adalimumab-atto) as a biosimilar to Humira® for multiple inflammatory diseases covered by the reference product label [3]. Additional adalimumab biosimilars such as ABP 501 (Amgen) and SB5 (Samsung Bioepis) are in Phase 3 development (see clinical trials NCT01970475 and NCT02167139 repectively) and FKB327 from Fujifilm Kyowa Kirin Biologics (NCT02260791 recently described in BJCP [6].